Related Experiment Video
Updated: May 13, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[What's new in oncology?].
1Service de Dermatologie, Centre Hospitalier Lyon Sud, 165, chemin du Grand Revoyet, 69495 Pierre Bénite cedex 08, France. stephane.dalle@chu-lyon.fr
Annales De Dermatologie Et De Venereologie
|March 26, 2013
Summary
2012 saw advances in cutaneous oncology, including targeted therapies like MAP-kinase inhibitors for melanoma and vismodegib for basal cell carcinoma. New questions arise regarding side effects of these innovative treatments.
Area of Science:
- Dermatology and Oncology
- Pharmacology and Therapeutics
Context:
- 2012 marked significant progress in cutaneous oncology with consolidated results and emerging therapeutic options.
- Established therapies include MAP-kinase inhibitors (anti-MEK, anti-BRAF) for metastatic melanoma.
- Vismodegib (SMO inhibitor) shows promise for advanced basal cell carcinomas and Gorlin syndrome.
Purpose:
- To review key advancements in cutaneous oncology from 2012.
- To highlight new therapeutic strategies and their clinical implications.
- To address emerging concerns regarding targeted therapy side effects.
Summary:
- Consolidated findings support MAP-kinase inhibitors (anti-MEK, anti-BRAF) for metastatic melanoma.
- Large-scale studies on vismodegib for basal cell carcinoma were published.
- New advances include PD1/PD-L1 inhibitors, combination therapies, and adjuvant treatments for melanoma.
Impact:
- Significant progress in treating metastatic melanoma and basal cell carcinoma.
- Emerging challenges include understanding and managing side effects of targeted therapies.
- Paradoxical side effects, such as secondary skin cancers, necessitate further research.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...